Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Mozobil; Belgium: Mozobil; Bulgaria: Mozobil; Czech Republic: Mozobil; Denmark: Mozobil; Estonia: Mozobil; Finland: Mozobil; France: Mozobil; Germany: Mozobil; Greece: Mozobil; Hungary: Mozobil; Ireland: Mozobil; Latvia: Mozobil; Lithuania: Mozobil; Luxembourg: Mozobil; Malta: Mozobil; Netherlands: Mozobil; Poland: Mozobil; Portugal: Mozobil; Romania: Mozobil; Slovakia: Mozobil; Slovenia: Mozobil; Spain: Mozobil; Sweden: Mozobil; UK: Mozobil.

North America

USA: Mozobil.

Drug combinations


Plerixafor: C~28~H~54~N~8~. Mw: 502.78. (1) 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane. (2) 1,1′-[1,4-phenylenebis (methylene)]-bis-1,4,8,11-tetraazacyclotetradecane. CAS-110078-46-1.

Pharmacologic Category

Hematopoietic Agents; Stem Cell Mobilizer. (ATC-Code: L03AX16).

Mechanism of action

Reversibly inhibits binding of stromal cell-derived factor-1-alpha (SDF-1α), expressed on bone marrow stromal cells, to the CXC chemokine receptor 4 (CXCR4), resulting in mobilization of hematopoietic stem and progenitor cells from bone marrow into peripheral blood. Plerixafor used in combination with filgrastim results in synergistic increase in CD34+ cell mobilization. Mobilized CD34+ cells are capable of engrafting with extended repopulating capacity.

Therapeutic use

Mobilization of hematopoietic stem cells (HSC) for collection and subsequent autologous transplantation (in combination with filgrastim) in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM).

Pregnancy and lactiation implications

May cause fetal harm; advise women not to become pregnant. Not recommended during lactation.

Unlabeled use


There are no contraindications listed within the manufacturer’s labeling.

Warnings and precautions

Increases circulating leukocytes when used in conjunction with filgrastim (monitor WBC and use with caution in patients with neutrophil count >50000/mm^3^). Thrombocytopenia has been observed (monitor platelet count). Not intended for mobilization in patients with leukemia (may contaminate apheresis product by mobilizing leukemic cells). Dosage reduction recommended in patients with moderate-severe renal impairment (CrCl ≤50 mL/minute). Tumor cell mobilization might occur (potential effect of tumor cell reinfusion is unknown). Splenomegaly and splenic rupture reported (rarely) with filgrastim use.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart